文献速递基础与转化研究临床试验与 GCP医学人工智能与信息学

潜在生物标志物效应下临床试验的最优设计:一种新型计算方法

The optimal design of clinical trials with potential biomarker effects: A novel computational approach.
PubMed 文献 · Stat Med · 2021-01-11

针对利用已发现但不确定的生物标志物亚组设计临床试验的难题,该研究将试验设计转化为含高维积分的优化问题,提出基于蒙特卡洛与平滑方法的计算解决方案,并利用GPU并行计算。在三维问题中,该方法较已发表方法更精确且快133倍,精度界不受维度影响,并提供了软件DesignCTPB。

要点

  • 将生物标志物引导的临床试验设计建模为高维积分优化问题。
  • 采用蒙特卡洛与平滑方法结合GPU并行计算求解。
  • 三维问题中较已发表方法更精确且快133倍,精度界不随维度增加而恶化。

核心结论

  • 提出一种可扩展的计算方法,用于设计利用潜在生物标志物效应的临床试验,其估计研究功效的精度界为有限数且不受维度影响。

研究设计与样本

  • 方法学研究:将临床试验设计形式化为涉及高维积分的优化问题,并提出基于蒙特卡洛与平滑方法的计算解决方案,利用GPU进行大规模并行计算。

主要发现

  • 在三维问题中,与一篇已发表方法相比,本方法更精确且快133倍。
  • 当维度增加时,该优势进一步增大。
  • 估计研究功效的精度界为有限数,不受维度影响,因此方法可扩展至高维问题。

临床怎么用

  • 用户可使用软件「DesignCTPB」设计纳入潜在生物标志物的临床试验,该软件可在Github获取并将作为R包在CRAN发布。

局限性

  • 原文未报告该方法在真实临床试验数据中的验证结果。
  • 原文未报告除三维问题外与其他方法的具体比较数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As a future trend of healthcare, personalized medicine tailors medical treatments to individual patients. It requires to identify a subset of patients with the best response to treatment. The subset can be defined by a biomarker (eg, expression of a gene) and its cutoff value. Topics on subset identification have received massive attention. There are over two million hits by keyword searches on Google Scholar. However, designing clinical trials that utilize the discovered uncertain subsets/biomarkers is not trivial and rarely discussed in the literature. This leads to a gap between research results and real-world drug development. To fill in this gap, we formulate the problem of clinical trial design into an optimization problem involving high-dimensional integration, and propose a novel computational solution based on Monte Carlo and smoothing methods. Our method utilizes the modern techniques of general purpose computing on graphics processing units for large-scale parallel computing. Compared to a published method in three-dimensional problems, our approach is more accurate and 133 times faster. This advantage increases when dimensionality increases. Our method is scalable to higher dimensional problems since the precision bound of our estimated study power is a finite number not affected by dimensionality. To design clinical trials incorporating the potential biomarkers, users can use our software "DesignCTPB". This software can be found on Github and will be available as an R package on CRAN. Although our research is motivated by the design of clinical trials, the method can be used widely to solve other optimization problems involving high-dimensional integration.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Lu Y, Zhou J, Xing L, et al. The optimal design of clinical trials with potential biomarker effects: A novel computational approach. Stat Med. 2021. PMID: 33426649. doi:10.1002/sim.8868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。